| scholarly article | Q13442814 |
| P50 | author | Sabina Janciauskiene | Q47158764 |
| P2093 | author name string | Susan Stewart | |
| David A Lomas | |||
| Ravi Mahadeva | |||
| Zhenjun Li | |||
| Carl Atkinson | |||
| Steven D Shapiro | |||
| Diane G Kelley | |||
| Jasvir Parmar | |||
| Rebecca Pitman | |||
| P2860 | cites work | Structure of a serpin-protease complex shows inhibition by deformation | Q24290459 |
| Effect of the Z mutation on the physical and inhibitory properties of alpha 1-antitrypsin | Q70534585 | ||
| Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of alpha 1-antitrypsin deficiency. Alpha 1-Antitrypsin Deficiency Registry Study Group | Q73092766 | ||
| Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with alpha(1)-antitrypsin deficiency (PiZ) | Q73251110 | ||
| Cytokines regulate membrane-bound leukocyte elastase on neutrophils: a novel mechanism for effector activity | Q73282197 | ||
| Structural insights into serpin-protease complexes reveal the inhibitory mechanism of serpins | Q73327199 | ||
| Detection of circulating and endothelial cell polymers of Z and wild type alpha 1-antitrypsin by a monoclonal antibody | Q74148034 | ||
| End-stage chronic obstructive pulmonary disease: the cigarette is burned out but inflammation rages on | Q74355197 | ||
| Genetic Epidemiology of COPD | Q77763667 | ||
| EXPERIMENTAL EMPHYSEMA: ITS PRODUCTION WITH PAPAIN IN NORMAL AND SILICOTIC RATS | Q78433888 | ||
| Chronic obstructive pulmonary disease | Q79106927 | ||
| Alpha1-antitrypsin polymerization and the serpinopathies: pathobiology and prospects for therapy | Q24554310 | ||
| Liver injury in alpha1-antitrypsin deficiency: an aggregated protein induces mitochondrial injury | Q24554312 | ||
| The serpin superfamily of proteinase inhibitors: structure, function, and regulation | Q28254893 | ||
| The nature of small-airway obstruction in chronic obstructive pulmonary disease | Q29618682 | ||
| The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature | Q29618777 | ||
| Neutrophil accumulation in the lung in alpha 1-antitrypsin deficiency. Spontaneous release of leukotriene B4 by alveolar macrophages | Q34198111 | ||
| Cirrhosis associated with alpha-1-antitrypsin deficiency: a previously unrecognized inherited disorder | Q34203754 | ||
| Human alpha 1-proteinase inhibitor. Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function | Q34255957 | ||
| The electrophoretic α1-globulin pattern of serum in α1-antitrypsin deficiency. 1963. | Q34335215 | ||
| The mechanism of Z alpha 1-antitrypsin accumulation in the liver | Q34440939 | ||
| Implications of the three-dimensional structure of alpha 1-antitrypsin for structure and function of serpins | Q34515383 | ||
| Sputum chemotactic activity in chronic obstructive pulmonary disease: effect of alpha(1)-antitrypsin deficiency and the role of leukotriene B(4) and interleukin 8 | Q35535330 | ||
| Chronic obstructive pulmonary disease: molecular and cellularmechanisms | Q35569962 | ||
| Z-type alpha 1-antitrypsin is less competent than M1-type alpha 1-antitrypsin as an inhibitor of neutrophil elastase | Q35581750 | ||
| Potential mechanism of emphysema: alpha 1-proteinase inhibitor recovered from lungs of cigarette smokers contains oxidized methionine and has decreased elastase inhibitory capacity | Q36288052 | ||
| Formation of the covalent serpin-proteinase complex involves translocation of the proteinase by more than 70 A and full insertion of the reactive center loop into beta-sheet A. | Q36331710 | ||
| Expression of the alpha-1-antitrypsin gene in mononuclear phagocytes of normal and alpha-1-antitrypsin-deficient individuals | Q36994663 | ||
| Antielastases of the human alveolar structures. Implications for the protease-antiprotease theory of emphysema | Q37004037 | ||
| Molecular basis of alpha-1-antitrypsin deficiency | Q39646899 | ||
| Animal models of emphysema | Q39726284 | ||
| The Pi polymorphism: genetic, biochemical, and clinical aspects of human alpha 1-antitrypsin. | Q40101093 | ||
| Biosynthesis of alpha1-proteinase inhibitor by human lung-derived epithelial cells | Q41120094 | ||
| Lung polymers in Z alpha1-antitrypsin deficiency-related emphysema | Q42454527 | ||
| Polymers of alpha(1)-antitrypsin are chemotactic for human neutrophils: a new paradigm for the pathogenesis of emphysema | Q42521815 | ||
| 6-mer peptide selectively anneals to a pathogenic serpin conformation and blocks polymerization. Implications for the prevention of Z alpha(1)-antitrypsin-related cirrhosis | Q43843392 | ||
| Lung lavage fluid from patients with alpha 1-proteinase inhibitor deficiency or chronic obstructive bronchitis: anti-elastase function and cell profile | Q43885242 | ||
| Experimental emphysema induced with purified human neutrophil elastase: tissue localization of the instilled protease | Q44384558 | ||
| Amplification of inflammation in emphysema and its association with latent adenoviral infection | Q44764238 | ||
| Structural basis for serpin inhibitor activity | Q45080412 | ||
| Z alpha1-antitrypsin polymerizes in the lung and acts as a neutrophil chemoattractant | Q47622881 | ||
| Clinical features and history of the destructive lung disease associated with alpha-1-antitrypsin deficiency of adults with pulmonary symptoms. | Q50567622 | ||
| Studies in alpha 1-antitrypsin deficiency. | Q54285259 | ||
| The Electrophoretic α;1-Globulin Pattern of Serum in α;1-Antitrypsin Deficiency | Q56224874 | ||
| Pathogenic α1-Antitrypsin Polymers Are Formed by Reactive Loop-β-Sheet A Linkage | Q57980256 | ||
| A Kinetic Mechanism for the Polymerization of α1-Antitrypsin | Q57980265 | ||
| Liver Disease in Alpha1-Antitrypsin Deficiency Detected by Screening of 200,000 Infants | Q66883467 | ||
| Structural evidence for methionine at the reactive site of human alpha-1-proteinase inhibitor | Q67393397 | ||
| Alpha 1-antitrypsin Pi-types in 965 COPD patients | Q68793944 | ||
| Risk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiency | Q68794479 | ||
| Human neutrophils express the alpha 1-antitrypsin gene and produce alpha 1-antitrypsin | Q70176397 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chemotaxis | Q658145 |
| P304 | page(s) | 377-386 | |
| P577 | publication date | 2005-02-01 | |
| P1433 | published in | The American Journal of Pathology | Q4744259 |
| P1476 | title | Polymers of Z alpha1-antitrypsin co-localize with neutrophils in emphysematous alveoli and are chemotactic in vivo | |
| P478 | volume | 166 |
| Q35124900 | ATZ11 recognizes not only Z-α1-antitrypsin-polymers and complexed forms of non-Z-α1-antitrypsin but also the von Willebrand factor |
| Q38092905 | Airway disease in alpha-1 antitrypsin deficiency |
| Q26995192 | Alpha-1-antitrypsin deficiency |
| Q36846798 | Alpha-1-antitrypsin deficiency: current concepts |
| Q38581002 | Alpha-1-antitrypsin deficiency: increasing awareness and improving diagnosis |
| Q93493568 | Alpha-Proteinase Inhibitor (Human) |
| Q47268961 | Alveolar injury and regeneration following deletion of ABCA3. |
| Q38937853 | An ECLIPSE View of Alpha-1 Antitrypsin Deficiency |
| Q37410570 | Antisense oligonucleotide treatment ameliorates alpha-1 antitrypsin-related liver disease in mice. |
| Q37774788 | Augmentation therapy in alpha-1 antitrypsin deficiency: advances and controversies |
| Q61796986 | Characterisation of a type II functionally-deficient variant of alpha-1-antitrypsin discovered in the general population |
| Q38933451 | Characterising the association of latency with α(1)-antitrypsin polymerisation using a novel monoclonal antibody |
| Q55315240 | Clarification of the risk of chronic obstructive pulmonary disease in α1-antitrypsin deficiency PiMZ heterozygotes. |
| Q49961017 | Diagnosing alpha-1 antitrypsin deficiency: the first step in precision medicine. |
| Q42680337 | Dietary vitamin D3 deficiency exacerbates sinonasal inflammation and alters local 25(OH)D3 metabolism |
| Q28547169 | Discovery of an inhibitor of Z-alpha1 antitrypsin polymerization |
| Q41943843 | Dynamic local unfolding in the serpin α-1 antitrypsin provides a mechanism for loop insertion and polymerization |
| Q36444154 | Enhancing Autophagy with Drugs or Lung-directed Gene Therapy Reverses the Pathological Effects of Respiratory Epithelial Cell Proteinopathy. |
| Q42176276 | Gene targeted therapeutics for liver disease in alpha-1 antitrypsin deficiency |
| Q24630805 | Genes and chronic obstructive pulmonary disease |
| Q37855343 | Hepatic fibrosis and carcinogenesis in α1-antitrypsin deficiency: a prototype for chronic tissue damage in gain-of-function disorders |
| Q21202920 | Hereditary alpha-1-antitrypsin deficiency and its clinical consequences |
| Q57980231 | Identification of a 4-mer Peptide Inhibitor that Effectively Blocks the Polymerization of Pathogenic Z α1-Antitrypsin |
| Q42590837 | Immunomodulation by alpha(1)-proteinase inhibitor: lack of chemotactic effects of recombinant human alpha(1)-proteinase inhibitor from yeast on human peripheral blood granulocytes |
| Q47643314 | Impact of HIV Infection on Alpha-1 Antitrypsin in the Lung |
| Q39085645 | Increased ERK signalling promotes inflammatory signalling in primary airway epithelial cells expressing Z α1-antitrypsin |
| Q46718946 | Inhaled corticosteroids as additional treatment in alpha-1-antitrypsin-deficiency-related COPD. |
| Q38912052 | Inhibitory serpins. New insights into their folding, polymerization, regulation and clearance |
| Q37341652 | Intracellular and extracellular serpins modulate lung disease |
| Q48027252 | Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE). |
| Q37804626 | Lung disease associated with alpha1-antitrypsin deficiency |
| Q59796548 | Lung function and CT lung densitometry in 37- to 39-year-old individuals with alpha-1-antitrypsin deficiency |
| Q37051733 | Multilineage transduction of resident lung cells in vivo by AAV2/8 for α1-antitrypsin gene therapy |
| Q38875787 | Neutrophil Fates in Bronchiectasis and Alpha-1 Antitrypsin Deficiency |
| Q36183894 | Neutrophilic inflammation and IL-8 levels in induced sputum of alpha-1-antitrypsin PiMZ subjects |
| Q38643507 | Neutrophilic panniculitis associated with alpha-1-antitrypsin deficiency: an update |
| Q37466723 | New Findings in PiZZ alpha1-antitrypsin deficiency-related panniculitis. Demonstration of skin polymers and high dosing requirements of intravenous augmentation therapy |
| Q51536039 | Oxidation of Z α1-antitrypsin by cigarette smoke induces polymerization: a novel mechanism of early-onset emphysema. |
| Q37343918 | Oxidized {alpha}1-antitrypsin stimulates the release of monocyte chemotactic protein-1 from lung epithelial cells: potential role in emphysema |
| Q43180243 | Parker B. Francis lectureship. Antitrypsin deficiency, the serpinopathies, and chronic obstructive pulmonary disease |
| Q37203729 | Polymers and inflammation: disease mechanisms of the serpinopathies |
| Q34928474 | Protein misfolding and the serpinopathies |
| Q42790541 | Proteostasis: a new therapeutic paradigm for pulmonary disease |
| Q35564231 | Randomised controlled crossover trial of humidified continuous positive airway pressure in mild obstructive sleep apnoea |
| Q23911017 | Rationale and design of the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis. Alpha-1 protocol |
| Q38988633 | Recent advances in understanding and treating COPD related to α1-antitrypsin deficiency |
| Q38111790 | Recent advances in α-1-antitrypsin deficiency-related lung disease |
| Q38827548 | Risk of Lung Disease in PI MZ Heterozygotes. Current Status and Future Research Directions |
| Q36634711 | Role of lung maintenance program in the heterogeneity of lung destruction in emphysema |
| Q37070325 | Roles for proteinases in the pathogenesis of chronic obstructive pulmonary disease |
| Q37303247 | Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency. |
| Q39899143 | Small-molecule peptides inhibit Z alpha1-antitrypsin polymerization |
| Q55259593 | The Multifaceted Effects of Alpha1-Antitrypsin on Neutrophil Functions. |
| Q36308010 | The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency. |
| Q55011363 | The impact of alpha-1 antitrypsin augmentation therapy on neutrophil-driven respiratory disease in deficient individuals. |
| Q41066319 | The pathological Trento variant of alpha-1-antitrypsin (E75V) shows nonclassical behaviour during polymerization |
| Q34256009 | The role of bronchial epithelial cells in the pathogenesis of COPD in Z-alpha-1 antitrypsin deficiency |
| Q37894093 | The role of proteases, endoplasmic reticulum stress and SERPINA1 heterozygosity in lung disease and α-1 anti-trypsin deficiency |
| Q36378692 | The selective advantage of alpha1-antitrypsin deficiency |
| Q57119419 | Therapeutic potential of alpha-1 antitrypsin in human disease |
| Q35214289 | Therapeutic targeting of misfolding and conformational change in α1-antitrypsin deficiency |
| Q35031693 | Therapy with plasma purified alpha1-antitrypsin (Prolastin®) induces time-dependent changes in plasma levels of MMP-9 and MPO. |
| Q38092851 | Twenty years of polymers: a personal perspective on alpha-1 antitrypsin deficiency |
| Q35233352 | Why has it been so difficult to prove the efficacy of alpha-1-antitrypsin replacement therapy? Insights from the study of disease pathogenesis |
| Q33901639 | Z α1-antitrypsin confers a proinflammatory phenotype that contributes to chronic obstructive pulmonary disease |
| Q85045909 | [COPD and alpha-1-antitrypsin deficiency] |
| Q37474870 | alpha1-Antitrypsin deficiency, chronic obstructive pulmonary disease and the serpinopathies |
| Q37855954 | α(1)-antitrypsin deficiency and inflammation |
| Q24633462 | α-1 Antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8 |
| Q51481224 | α1-Antitrypsin deficiency. |
Search more.